Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free MESO Stock Alerts

Mesoblast (MESO) News Today

Mesoblast logo
$17.00 -0.43 (-2.47%)
As of 08/21/2026 04:00 PM Eastern
Compare

Mesoblast Latest News

Mesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?
August 21 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mesoblast-nasdaqmeso-shares-gap-down-time-to-sell-2026-08-21/
Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment
August 19, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/mesoblast-shares-jump-as-phase-3-chronic-back-pain-trial-completes-patient-treatment/ar-AA2aiztD
Mesoblast (NASDAQ:MESO) Shares Gap Up - Here's What Happened
August 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30970409
Mesoblast Completes Pivotal Phase 3 Patient Treatment for Chronic Low Back Pain
August 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-completes-pivotal-phase-3-patient-treatment-for-chronic-low-back-pain?utm_source=marketbeat.com&utm_medium=referral
Mesoblast share price jumps on blockbuster news
August 17, 2026  |  fool.com.auhttps://www.fool.com.au/2026/08/17/mesoblast-share-price-jumps-on-blockbuster-news/
Mesoblast shares are up sharply. Is this biotech still undervalued?
August 17, 2026  |  msn.comhttps://www.msn.com/en-au/money/general/mesoblast-shares-are-up-sharply-is-this-biotech-still-undervalued/ar-AA2ajvgr
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
August 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3345802/0/en/mesoblast-achieves-major-milestone-completing-patient-treatment-in-pivotal-phase-3-trial-for-chronic-low-back-pain.html
Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial
August 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=marketbeat.com&utm_medium=referral
Mesoblast Limited 2026 Q4 - Results - Earnings Call Presentation
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935528-mesoblast-limited-2026-q4-results-earnings-call-presentation
Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mesoblast-nasdaqmeso-shares-gap-up-whats-next-2026-08-10/
Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB
July 30, 2026  |  fool.com.auhttps://www.fool.com.au/2026/07/30/mesoblast-fy26-earnings-ryoncil-revenue-up-new-trial-milestones-for-asxmsb/
Mesoblast (MESO) Q2 2026 Earnings
July 30, 2026  |  247wallst.comhttps://247wallst.com/cards/mesoblast-q2-2026-earnings-meso-01kysfj4mhccakecg47nhh6623
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3335700/0/en/mesoblast-reports-ryoncil-net-revenues-of-us-36m-for-the-quarter-and-us-115m-for-first-full-year-of-product-launch.html
Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors ...
July 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/degenerative-disc-disease-market-observe-143100220.html
HotCopper highlights, week 29: Dimerix licensing, lithium, & a Mesoblast milestone
July 17, 2026  |  msn.comhttps://www.msn.com/en-au/money/news/hotcopper-highlights-week-29-dimerix-licensing-lithium-a-mesoblast-milestone/ar-AA286jXF
Mesoblast Advances Rexlemestrocel‑L BLA for High‑Risk LVAD Heart Failure Patients
July 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MEOBF/pressreleases/3089746/mesoblast-advances-rexlemestrocell-bla-for-highrisk-lvad-heart-failure-patients/
Regulators cleared the first cell therapy for a deadly complication of blood-cancer transplants
July 16, 2026  |  msn.comhttps://www.msn.com/en-us/science/biology/regulators-cleared-the-first-cell-therapy-for-a-deadly-complication-of-blood-cancer-transplants/ar-AA284Bv1
Tuesday's HotCopper trends: Mesoblast, AuKing Mining, Tusker Minerals, and other daily topics
July 14, 2026  |  msn.comhttps://www.msn.com/en-au/money/news/tuesdays-hotcopper-trends-mesoblast-auking-mining-tusker-minerals-and-other-daily-topics/ar-AA27R3FP
Mesoblast CEO’s Duplicative Options Lapse With No Change to Shareholding
July 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-ceos-duplicative-options-lapse-with-no-change-to-shareholding?utm_source=marketbeat.com&utm_medium=referral
Mesoblast Issues 8.2 Million Unquoted Employee Options
July 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-issues-8-2-million-unquoted-employee-options?utm_source=marketbeat.com&utm_medium=referral
Mesoblast Expands Ordinary Share Base Through Conversion of Unquoted Securities
July 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-expands-ordinary-share-base-through-conversion-of-unquoted-securities?utm_source=marketbeat.com&utm_medium=referral
Mesoblast Cancels Over 1.2 Million Lapsed Options
July 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-cancels-over-1-2-million-lapsed-options?utm_source=marketbeat.com&utm_medium=referral
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/14/3326541/0/en/mesoblast-achieves-target-of-300-treated-patients-in-pivotal-phase-3-trial-for-chronic-low-back-pain.html
Mesoblast Hits 300‑Patient Milestone in Pivotal Back Pain Trial
July 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-hits-300patient-milestone-in-pivotal-back-pain-trial?utm_source=marketbeat.com&utm_medium=referral
Why Mesoblast shares could double in value
July 12, 2026  |  fool.com.auhttps://www.fool.com.au/2026/07/13/why-mesoblast-shares-could-double-in-value/
Mesoblast posts quarterly revenue uptick from Ryoncil sales
July 11, 2026  |  msn.comhttps://www.msn.com/en-au/money/general/mesoblast-posts-quarterly-revenue-uptick-from-ryoncil-sales/ar-AA27G7U2
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
July 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4921361-mesoblast-the-commercial-proof-is-now-becoming-the-investment-thesis
Mesoblast Limited: Ryoncil Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
July 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68993653-mesoblast-limited-ryoncil-delivers-net-revenue-of-us-dollar-36m-for-the-fourth-quarter-ended-30-june-2026-399.htm
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
July 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/10/3325284/0/en/ryoncil-delivers-net-revenue-of-us-36m-for-the-fourth-quarter-ended-30-june-2026.html
Mesoblast posts US$115m first-year Ryoncil revenue and strengthens capital position
July 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-posts-us115m-first-year-ryoncil-revenue-and-strengthens-capital-position?utm_source=marketbeat.com&utm_medium=referral
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320270/0/en/mesoblast-receives-bla-filing-number-and-requests-modular-review-for-rexlemestrocel-l-in-patients-with-end-stage-heart-failure-and-lvads.html
JPMorgan exits substantial holder position in Mesoblast
June 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3042483/jpmorgan-exits-substantial-holder-position-in-mesoblast/
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317246/0/en/mesoblast-draws-us-50-million-from-five-year-non-dilutive-facility.html
Mesoblast Taps US$50m Low-Cost Facility to Retire High-Cost Debt and Fund Growth
June 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-taps-us50m-low-cost-facility-to-retire-high-cost-debt-and-fund-growth?utm_source=marketbeat.com&utm_medium=referral
Why is this ASX biotech stock blasting higher today?
June 18, 2026  |  msn.comhttps://www.msn.com/en-au/money/general/why-is-this-asx-biotech-stock-blasting-higher-today/ar-AA25Vzbp
Mesoblast Highlights Growth Prospects and Risks in CEO Investor Presentation
June 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MEOBF/pressreleases/2272009/mesoblast-highlights-growth-prospects-and-risks-in-ceo-investor-presentation/
Mesoblast Limited (MESO) Presents at ASX CEO Connect June 2026 - Slideshow
June 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4912188-mesoblast-limited-meso-presents-at-asx-ceo-connect-june-2026-slideshow
3 reasons why this ASX biotech stock could double in value
May 11, 2026  |  fool.com.auhttps://www.fool.com.au/2026/05/12/3-reasons-why-this-asx-biotech-stock-could-double-in-value/
How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story
May 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/completion-rmat-phase-3-enrollment-221934553.html
Mesoblast Ramps Up Ryoncil Sales, Advances Late-Stage Cell Therapy Pipeline
April 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-ramps-up-ryoncil-sales-advances-late-stage-cell-therapy-pipeline?utm_source=marketbeat.com&utm_medium=referral
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284394/0/en/mesoblast-reports-ryoncil-net-revenues-of-us-30-3m-and-improved-net-operating-cash-spend-for-the-quarter-to-us-4-1-million.html
A big milestone for this ASX biotech. Here's why the share price is moving
April 29, 2026  |  msn.comhttps://www.msn.com/en-au/health/healthy-lifestyle/a-big-milestone-for-this-asx-biotech-heres-why-the-share-price-is-moving/ar-AA21XMT4
Mesoblast shares in focus after key phase 3 milestone for low back pain
April 29, 2026  |  msn.comhttps://www.msn.com/en-au/health/healthy-lifestyle/mesoblast-shares-in-focus-after-key-phase-3-milestone-for-low-back-pain/ar-AA21X5To
Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital Platform
April 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/mesoblast-ltd-meso-secure-exclusive-173005276.html
Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth Signals
April 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/assessing-mesoblast-valuation-recent-share-020810392.html
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283366/0/en/Mesoblast-Achieves-Patient-Recruitment-Target-in-Pivotal-Phase-3-Trial-for-Chronic-Low-Back-Pain.html
Mesoblast Hits Phase 3 Recruitment Milestone in Chronic Back Pain Push
April 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mesoblast-hits-phase-3-recruitment-milestone-in-chronic-back-pain-push?utm_source=marketbeat.com&utm_medium=referral
Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in
April 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/why-mesoblast-limited-meso-one-001134379.html
Mesoblast Issues 3.28 Million New Shares on Option Conversions
April 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MEOBF/pressreleases/1361467/mesoblast-issues-328-million-new-shares-on-option-conversions/
Mesoblast Reports Lapse of 723,666 Options, Reducing Potential Dilution
April 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MEOBF/pressreleases/1361457/mesoblast-reports-lapse-of-723666-options-reducing-potential-dilution/

Mesoblast Media Mentions By Week

Mesoblast Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MESO
News Sentiment
▼
0.01

0.64
▲
Average
Healthcare
News Sentiment

Mesoblast News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MESO Articles
This Week
▼
8

3
▲
MESO Articles
Average Week

Mesoblast Trends on MarketBeat

This week vs. last week
Searches
1
Page Views
1,463
+5%
Get Mesoblast News Delivered to You Automatically

Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

This page (NASDAQ:MESO) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel